• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜血管疾病的管理:以患者为中心的方法。

Management of retinal vascular diseases: a patient-centric approach.

机构信息

Eye Department, Royal Hallamshire Hospital, Sheffield, UK.

出版信息

Eye (Lond). 2012 Apr;26 Suppl 2(Suppl 2):S1-16. doi: 10.1038/eye.2012.32.

DOI:10.1038/eye.2012.32
PMID:22495396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335302/
Abstract

Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the clinical management of these diseases has been fast-paced, with new treatments becoming available as well as license extensions of existing treatments. Vascular endothelial growth factor (VEGF) has been implicated in certain retinal vascular diseases, including wet age-related macular degeneration (AMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO). Treatment of wet AMD and visual impairment due to either DMO or macular oedema secondary to RVO with an anti-VEGF on an as needed basis, rather than a fixed schedule, allows an individualised treatment approach; providing treatment when patients are most likely to benefit from it, while minimising the number of unnecessary intravitreal injections. Thus, an individualised treatment regimen reduces the chances of over-treatment and under-treatment, optimising both the risk/benefit profile of the treatment and the efficient use of NHS resource. Streamlining of treatment for patients with wet AMD and visual impairment due to either DMO or macular oedema secondary to RVO, by using one treatment with similar posology across all three diseases, may help to minimise burden of clinic capacity and complexity and hence optimise patient outcomes. Informed treatment decisions and efficient clinic throughput are important for optimal patient outcomes in the fast-changing field of retinal vascular diseases.

摘要

视网膜血管疾病是西方世界致盲的主要原因。这些疾病的临床管理进展迅速,新的治疗方法不断涌现,现有的治疗方法也获得了许可扩展。血管内皮生长因子(VEGF)与某些视网膜血管疾病有关,包括湿性年龄相关性黄斑变性(AMD)、糖尿病性黄斑水肿(DMO)和视网膜静脉阻塞(RVO)。湿性 AMD 以及由 DMO 或继发于 RVO 的黄斑水肿引起的视力障碍,按需而非固定时间间隔用抗 VEGF 治疗,允许采用个体化治疗方法;在患者最有可能受益的情况下提供治疗,同时最大限度地减少不必要的玻璃体内注射次数。因此,个体化治疗方案可降低过度治疗和治疗不足的可能性,优化治疗的风险/获益情况并提高 NHS 资源的使用效率。对于湿性 AMD 以及由 DMO 或继发于 RVO 的黄斑水肿引起的视力障碍患者,通过使用三种疾病中均具有相似治疗方案的一种治疗方法,可有助于最大限度地减少临床容量和复杂性负担,从而优化患者的治疗效果。在快速变化的视网膜血管疾病领域,明智的治疗决策和高效的临床治疗流程对于获得最佳患者治疗效果非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/02ced97b6d8b/eye201232f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/a10894ed280b/eye201232f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/c4f2172f083f/eye201232f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/75456e429b0d/eye201232f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/945221c00542/eye201232f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/02ced97b6d8b/eye201232f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/a10894ed280b/eye201232f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/c4f2172f083f/eye201232f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/75456e429b0d/eye201232f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/945221c00542/eye201232f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4134/3335302/02ced97b6d8b/eye201232f5.jpg

相似文献

1
Management of retinal vascular diseases: a patient-centric approach.视网膜血管疾病的管理:以患者为中心的方法。
Eye (Lond). 2012 Apr;26 Suppl 2(Suppl 2):S1-16. doi: 10.1038/eye.2012.32.
2
Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.抗血管内皮生长因子治疗视网膜疾病:系统评价和荟萃分析。
BMJ Open. 2019 May 28;9(5):e022031. doi: 10.1136/bmjopen-2018-022031.
3
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.接受前期治疗的年龄相关性黄斑变性、糖尿病性黄斑水肿、视网膜静脉阻塞和近视性脉络膜新生血管患者的五年视力预后和注射模式。
Br J Ophthalmol. 2017 Mar;101(3):353-359. doi: 10.1136/bjophthalmol-2016-308668. Epub 2016 May 23.
4
Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.视网膜疾病抗血管内皮生长因子治疗期间视力与视网膜厚度的关系
Am J Ophthalmol. 2017 Aug;180:8-17. doi: 10.1016/j.ajo.2017.05.014. Epub 2017 May 24.
5
Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.抗血管内皮生长因子治疗视网膜中央静脉阻塞继发黄斑水肿的荟萃分析。
Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):637-49. doi: 10.1111/ceo.12286. Epub 2014 Jan 27.
6
Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.玻璃体内注射贝伐单抗治疗糖尿病性黄斑水肿和视网膜中央静脉阻塞所致黄斑水肿后细胞因子水平的六个月变化。
Br J Ophthalmol. 2015 Oct;99(10):1334-40. doi: 10.1136/bjophthalmol-2014-306341. Epub 2015 Apr 3.
7
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.抗血管内皮生长因子治疗视网膜分支静脉阻塞继发的黄斑水肿。
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009510. doi: 10.1002/14651858.CD009510.pub2.
8
Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.视网膜内层紊乱与抗血管内皮生长因子治疗视网膜静脉阻塞继发黄斑水肿的视力反应的相关性研究。
JAMA Ophthalmol. 2019 Jan 1;137(1):38-46. doi: 10.1001/jamaophthalmol.2018.4484.
9
Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.玻璃体腔内抗血管内皮生长因子药物的潜在抗水肿作用,与中和血管内皮生长因子无关。
Drug Discov Today. 2019 Aug;24(8):1436-1439. doi: 10.1016/j.drudis.2019.05.034. Epub 2019 Jun 4.
10
Reading speed improvements in retinal vein occlusion after ranibizumab treatment.雷珠单抗治疗视网膜静脉阻塞后阅读速度的提高。
JAMA Ophthalmol. 2013 Jul;131(7):851-6. doi: 10.1001/jamaophthalmol.2013.114.

引用本文的文献

1
The Impact of the Foveal Bulge on Visual Acuity in Resolved Diabetic Macular Edema and Retinal Vein Occlusions.黄斑隆起对已消退的糖尿病性黄斑水肿和视网膜静脉阻塞患者视力的影响。
Cureus. 2024 Dec 11;16(12):e75543. doi: 10.7759/cureus.75543. eCollection 2024 Dec.
2
Exploring New Therapeutic Avenues for Ophthalmic Disorders: Glaucoma-Related Molecular Docking Evaluation and Bibliometric Analysis for Improved Management of Ocular Diseases.探索眼科疾病的新治疗途径:青光眼相关分子对接评估及文献计量分析以改善眼部疾病管理
Bioengineering (Basel). 2023 Aug 20;10(8):983. doi: 10.3390/bioengineering10080983.
3
Hyper-reflective dots in optical coherence tomography imaging and inflammation markers in diabetic retinopathy.

本文引用的文献

1
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.地塞米松玻璃体内植入物治疗与分支或中央视网膜静脉阻塞相关的黄斑水肿患者的 12 个月研究结果。
Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20.
2
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的持续获益:一项 III 期研究的 12 个月结果。
Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.
3
光学相干断层扫描成像中的高反射点与糖尿病视网膜病变中的炎症标志物。
J Anat. 2023 Oct;243(4):697-705. doi: 10.1111/joa.13889. Epub 2023 May 24.
4
Improving retinal vascular endothelial cell tropism through rational rAAV capsid design.通过合理的 rAAV 衣壳设计提高视网膜血管内皮细胞趋向性。
PLoS One. 2023 May 11;18(5):e0285370. doi: 10.1371/journal.pone.0285370. eCollection 2023.
5
Embedding Patient-Centricity by Collaborating with Patients to Transform the Rare Disease Ecosystem.通过与患者合作,将以患者为中心的理念嵌入其中,从而改变罕见病生态系统。
Pharmaceut Med. 2023 Jul;37(4):265-273. doi: 10.1007/s40290-023-00474-y. Epub 2023 May 4.
6
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes.英国糖尿病性黄斑水肿患者标准护理玻璃体内阿柏西普治疗实践评估:DRAKO 研究结果。
Eye (Lond). 2023 Aug;37(12):2527-2534. doi: 10.1038/s41433-022-02367-x. Epub 2023 Jan 18.
7
Neurovascular injury associated non-apoptotic endothelial caspase-9 and astroglial caspase-9 mediate inflammation and contrast sensitivity decline.神经血管损伤相关的非凋亡性内皮 Caspase-9 和星形胶质细胞 Caspase-9 介导炎症和对比敏感度下降。
Cell Death Dis. 2022 Nov 8;13(11):937. doi: 10.1038/s41419-022-05387-3.
8
Paeoniflorin alleviates the progression of retinal vein occlusion via inhibiting hypoxia inducible factor-1α/vascular endothelial growth factor/STAT3 pathway.芍药苷通过抑制低氧诱导因子-1α/血管内皮生长因子/STAT3 通路减轻视网膜静脉阻塞的进展。
Bioengineered. 2022 May;13(5):13622-13631. doi: 10.1080/21655979.2022.2081755.
9
A 3D finite element model to study the cavitation induced stresses on blood-vessel wall during the ultrasound-only phase of photo-mediated ultrasound therapy.一个用于研究光介导超声治疗仅超声阶段空化对血管壁产生的应力的三维有限元模型。
AIP Adv. 2022 Apr 19;12(4):045020. doi: 10.1063/5.0082429. eCollection 2022 Apr.
10
Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience.新冠病毒-19对黄斑新生血管形成和视网膜静脉阻塞治疗的影响:单中心经验
Biomed Hub. 2021 Dec 8;6(3):145-152. doi: 10.1159/000519565. eCollection 2021 Sep-Dec.
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
雷珠单抗治疗视网膜分支静脉阻塞继发黄斑水肿的持续获益:一项 III 期研究的 12 个月结果。
Ophthalmology. 2011 Aug;118(8):1594-602. doi: 10.1016/j.ophtha.2011.02.022.
4
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
5
Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.雷珠单抗灵活给药方案治疗新生血管性年龄相关性黄斑变性的安全性和有效性:SUSTAIN 研究。
Ophthalmology. 2011 Apr;118(4):663-71. doi: 10.1016/j.ophtha.2010.12.019.
6
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.RESTORE 研究:雷珠单抗单药治疗或联合激光治疗与单纯激光治疗糖尿病黄斑水肿的比较。
Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031.
7
Management of macular edema secondary to central retinal vein occlusion: an evidence-based.治疗视网膜中央静脉阻塞继发黄斑水肿的管理:循证医学。
Adv Ther. 2011 Jan;28(1):40-50. doi: 10.1007/s12325-010-0088-4. Epub 2010 Dec 9.
8
Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update.继发于分支视网膜静脉阻塞的黄斑水肿的管理:基于证据的更新。
Adv Ther. 2011 Jan;28(1):28-39. doi: 10.1007/s12325-010-0089-3. Epub 2010 Dec 9.
9
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.每月与每季度雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效和安全性:EXCITE 研究。
Ophthalmology. 2011 May;118(5):831-9. doi: 10.1016/j.ophtha.2010.09.004. Epub 2010 Dec 13.
10
The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application.补体系统对年龄相关性黄斑变性发病机制的意义——当前的证据及其向临床应用的转化。
Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):163-74. doi: 10.1007/s00417-010-1568-6. Epub 2010 Dec 3.